![](https://www.canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBa1VFIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--343423ae6e9242f786567707a57aed27b576cfb9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Logos.png)
Pathios Therapeutics
Pathios is developing small-molecule drugs that target acid-sensing GPCRs on the cells of the adaptive and innate immune systems.
Website
pathiostherapeutics.comPartner
Brent AhrensInvestment
Series A
Pathios is developing small-molecule drugs that target acid-sensing GPCRs on the cells of the adaptive and innate immune systems.
Series A